Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

TABLE 2

Deconvolution and regularity analysis

NN2211 Placebo P
Deconvolution analysis—baseline period
    insulin secretory burst mass (pmol · l−1 · pulse−1) 24 ± 14 22 ± 14 NS
    insulin secretory burst amplitude (pmol · l−1 · min−1) 10.3 ± 5.5 9.1 ± 5.3 NS
    basal insulin secretion (pmol · l−1 · min−1) 8.1 ± 3.3 6.5 ± 3.0 0.04
    interpulse interval (minutes) 5.8 ± 0.7 5.8 ± 1.0 NS
Baseline insulin pulse regularity
    ApEn (m = 1, r = 0.2 × SD) 1.41 ± 0.07 1.38 ± 0.11 NS
    ApEn (m = 1, r = 1.0 × SD) 0.65 ± 0.07 0.65 ± 0.08 NS
Glucose pulse entrainment
    spectral power 7.3 ± 3.9 4.9 ± 2.3 NS (0.095)
    autocorrelation coefficient 0.16 ± 0.13 0.11 ± 0.17 NS (0.066)
    ApEn (m = 1, r = 0.2 × SD) 1.36 ± 0.07 1.36 ± 0.05 NS
    ApEn (m = 1, r = 1.0 × SD) 0.64 ± 0.08 0.65 ± 0.07 NS
  • Results from time series analysis of insulin concentration time series obtained during baseline conditions and during glucose pulse entrainment with 6 mg/kg every 10 min. NS, not significant, if 0.1 > P > 0.05 the value is given in brackets.

This Article

  1. Diabetes vol. 51 no. 2 424-429